Building a true strategy about your pharmaceutical drugability 
Years of experience
Clients
Studied molecules
Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Latest news
AFSSI Connexions 2022
Back to the images of the 2022 AFSSI Connexions in Lyon (5th and 6th of July) → https://www.afssi-connexions.fr/ After 2 years in digital, it was great to meet in person all the association's actors...
more news>